GIFOF
Grifols, S.A.
Set alert
- YTD
- -17.25%
- 1 year
- -17.25%
- Open
- 8.85
- Prev close
- 7.29
- Mkt cap
- 4.96B
- Vol
- 149
- Avg vol
- 44
- EPS
- 0.77
- P/E
- 9.47
More statistics
- Low
- 8.85
- High
- 8.85
- Earnings
- Nov 10, 2026
News
2 months ago seekingalpha.com
Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following…
3 months ago seekingalpha.com
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue…
4 months ago globenewswire.com
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S.…
5 months ago seekingalpha.com
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript